SOLANA BEACH, Calif. — Artelo Biosciences Inc. appointed Mark Spring, CPA, Chief Financial Officer, effective November 1. Spring had been serving as a financial consultant to the company since December 2024. The appointment strengthens Artelo’s financial leadership as it advances its clinical pipeline and corporate growth initiatives.
Spring brings 30 years of experience in life sciences to his role, including financial leadership of private and public, domestic and multinational, commercial and development-stage companies. He recently served as interim CFO for LENZ Therapeutics through its reverse merger transaction and was co-founder and CFO of Secura Bio, a commercial-stage oncology therapeutics company. He also served as CFO for Hyperion Therapeutics, Prometheus Laboratories, Veracyte, Sotera Wireless, and Genoptix. Spring has extensive M&A and licensing experience with significant roles in major transactions at Caremark, Dade Behring, Baxter, MedImmune, Prometheus, and Genoptix. He holds a BA in Business Administration from Monmouth College, completed postgraduate studies at the University of Texas at Dallas, and is a Certified Public Accountant (active).
Related Articles:
